Filing Summary
Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed a Form 8-K reporting an amendment to a securities purchase agreement. The report date and earliest reported event were April 6, 2023; the filing was signed April 10, 2023. The company is listed on the Nasdaq Capital Market under the symbol UNCY.
Material Agreement and Corporate Action
On April 6, 2023, the company and the investors party to its March 3, 2023 Securities Purchase Agreement entered into Amendment No. 1. The amendment changes the proposed reverse stock split ratio range to between 1-for-2 and 1-for-20, replacing the prior proposed range of 1-for-10 to 1-for-20.
The company intends to seek stockholder approval of a specific reverse split ratio within the revised range at its upcoming annual meeting. The filing does not identify the final ratio or confirm that stockholder approval has been obtained.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial metrics.
Guidance, Risks, and Unusual Items
The principal disclosed development is the potential reverse stock split and the related amendment to the securities purchase agreement. Implementation remains subject to the applicable stockholder approval process and selection of a specific ratio. The filing does not provide management guidance or a broader business outlook.
Investor Verification Points
- Verify the complete terms of Amendment No. 1, filed as Exhibit 10.1.
- Confirm the date and outcome of the annual meeting vote.
- Confirm the final reverse split ratio, if approved, and its effective date.
- Review related subsequent filings for any changes to the securities purchase agreement or financing terms.